Publicaciones (23) Publicaciones de Cristina Martín Higueras

2024

  1. Multicenter Long-Term Real World Data on Treatment With Lumasiran in Patients With Primary Hyperoxaluria Type 1

    Kidney International Reports, Vol. 9, Núm. 1, pp. 114-133

2023

  1. Correction to: Three Tesla magnetic resonance imaging detects oxalate osteopathy in patients with primary hyperoxaluria type I (Pediatric Nephrology, (2023), 38, 7, (2083-2092), 10.1007/s00467-022-05836-3)

    Pediatric Nephrology

  2. Determinants of Kidney Failure in Primary Hyperoxaluria Type 1: Findings of the European Hyperoxaluria Consortium

    Kidney International Reports, Vol. 8, Núm. 10, pp. 2029-2042

  3. Simple, fast and inexpensive quantification of glycolate in the urine of patients with primary hyperoxaluria type 1

    Urolithiasis, Vol. 51, Núm. 1, pp. 49

  4. Three Tesla magnetic resonance imaging detects oxalate osteopathy in patients with primary hyperoxaluria type I

    Pediatric Nephrology, Vol. 38, Núm. 7, pp. 2083-2092

2022

  1. Chronic liver disease and hepatic calcium-oxalate deposition in patients with primary hyperoxaluria type I

    Scientific Reports, Vol. 12, Núm. 1

  2. Diet-related urine collections: assistance in categorization of hyperoxaluria

    Urolithiasis, Vol. 50, Núm. 2, pp. 141-148

  3. Disorders of Oxalate Metabolism

    Physician's Guide to the Diagnosis, Treatment, and Follow-Up of Inherited Metabolic Diseases, Second Edition (Springer International Publishing), pp. 1319-1332

  4. Improving Treatment Options for Primary Hyperoxaluria

    Drugs, Vol. 82, Núm. 10, pp. 1077-1094

  5. Nephrolithiasis and nephrocalcinosis in children and adolescents

    Urologie, Vol. 61, Núm. 10, pp. 1099-1109

  6. New salicylic acid derivatives, double inhibitors of glycolate oxidase and lactate dehydrogenase, as effective agents decreasing oxalate production

    European Journal of Medicinal Chemistry, Vol. 237

2021

  1. A report from the European Hyperoxaluria Consortium (OxalEurope) Registry on a large cohort of patients with primary hyperoxaluria type 3

    Kidney International

  2. Is stiripentol truly effective for treating primary hyperoxaluria?

    Clinical Kidney Journal

2020

  1. Inherited conditions resulting in nephrolithiasis

    Current opinion in pediatrics, Vol. 32, Núm. 2, pp. 273-283

  2. Is stiripentol truly effective for treating primary hyperoxaluria?

    Clinical Kidney Journal, Vol. 14, Núm. 1, pp. 442-444

2019

  1. Systemic Alanine Glyoxylate Aminotransferase mRNA Improves Glyoxylate Metabolism in a Mouse Model of Primary Hyperoxaluria Type 1

    Nucleic Acid Therapeutics, Vol. 29, Núm. 2, pp. 104-113

2018

  1. CRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I

    Nature Communications, Vol. 9, Núm. 1

  2. Salicylic Acid Derivatives Inhibit Oxalate Production in Mouse Hepatocytes with Primary Hyperoxaluria Type 1

    Journal of Medicinal Chemistry, Vol. 61, Núm. 16, pp. 7144-7167

  3. Specific Inhibition of Hepatic Lactate Dehydrogenase Reduces Oxalate Production in Mouse Models of Primary Hyperoxaluria

    Molecular Therapy, Vol. 26, Núm. 8, pp. 1983-1995

2017

  1. Molecular therapy of primary hyperoxaluria

    Journal of Inherited Metabolic Disease, Vol. 40, Núm. 4, pp. 481-489